Penserra Capital Management LLC Has $210,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Penserra Capital Management LLC lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4,366.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 402 shares of the biopharmaceutical company’s stock after buying an additional 393 shares during the quarter. Penserra Capital Management LLC’s holdings in Regeneron Pharmaceuticals were worth $210,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Activest Wealth Management lifted its position in Regeneron Pharmaceuticals by 110.5% during the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 21 shares during the last quarter. Costello Asset Management INC bought a new position in shares of Regeneron Pharmaceuticals in the first quarter worth about $27,000. Saudi Central Bank acquired a new position in shares of Regeneron Pharmaceuticals during the 1st quarter worth about $27,000. Colonial Trust Advisors bought a new stake in Regeneron Pharmaceuticals during the 1st quarter valued at approximately $32,000. Finally, SouthState Corp grew its holdings in Regeneron Pharmaceuticals by 550.0% in the 1st quarter. SouthState Corp now owns 52 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 44 shares during the last quarter. 83.31% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have recently commented on REGN shares. Redburn Atlantic upgraded Regeneron Pharmaceuticals to a “strong-buy” rating in a report on Thursday, August 14th. Jefferies Financial Group upped their target price on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a “buy” rating in a research note on Wednesday, August 27th. Weiss Ratings restated a “hold (c-)” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 8th. Wall Street Zen lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday. Finally, Royal Bank Of Canada increased their target price on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the company a “sector perform” rating in a research note on Wednesday, October 29th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $796.57.

Insider Activity at Regeneron Pharmaceuticals

In other news, Director Christine A. Poon sold 6,500 shares of the business’s stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total value of $4,252,755.00. Following the sale, the director owned 2,352 shares in the company, valued at approximately $1,538,843.04. The trade was a 73.43% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Jason Pitofsky sold 431 shares of the company’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the sale, the vice president directly owned 4,233 shares in the company, valued at approximately $2,757,503.19. The trade was a 9.24% decrease in their position. The disclosure for this sale is available in the SEC filing. 7.02% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $681.72 on Thursday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.06. The company has a 50-day moving average of $593.81 and a 200-day moving average of $569.58. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $823.56. The company has a market capitalization of $71.65 billion, a price-to-earnings ratio of 16.32, a PEG ratio of 2.03 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, beating analysts’ consensus estimates of $9.73 by $2.10. The business had revenue of $3.75 billion for the quarter, compared to analysts’ expectations of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The firm’s revenue for the quarter was up .9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $12.46 earnings per share. As a group, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, December 5th. Investors of record on Thursday, November 20th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.5%. The ex-dividend date is Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.43%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.